• 1
    Parsonage MJ, Wilkins EGL, Snowden N et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med 2005; 6: 341346.
  • 2
    Izzedine H, Isnard-Begnis C, Hulot J-S et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18: 10741076.
  • 3
    Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830838.
  • 4
    Huang E, Hewitt R, Shelton M, Morse GD. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 1996; 16: 222229.
  • 5
    Corsonello A, Pedone C, Corica F et al. Concealed renal failure and adverse drug reactions in older patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci 2005; 60: 11471151.
  • 6
    Levey A, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461470.
  • 7
    Gupta SK, Eustace JA, Winston JA et al. Guidelines for the management of chronic kidney disease in HIV-infected patients. Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2005; 40: 15591585.
  • 8
    Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population. Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41: 112.
  • 9
    Kearney BP, Mittan A, Sayre J et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 2003 [Abstract A-1617].
  • 10
    Zong J, Chittick G, Blum MR et al. Pharmacokinetic assessment of tenofovir DF and ritonavir-boosted saquinavir in healthy subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, October 2004 [Abstract A-444].
  • 11
    Boehringer Ingelheim Pharmaceuticals Inc. Aptivus Prescribing Information. Ridgefield, CN, Boehringer Ingelheim Pharmaceuticals Inc., 2005.
  • 12
    Gilead Sciences Inc. Viread Prescribing Information. Foster City, CA, Gilead Sciences Inc., 2005.
  • 13
    Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J Am Med Assoc 2004; 292: 191201.